Decisions / 7817
final resolution2026-05-12active

Arzneimittel-Richtlinie/Anlage XII: Trastuzumab deruxtecan (Neue wissenschaftliche Erkenntnisse § 14: Adenokarzinom des Magens oder des gastroösophagealen Übergangs, HER2+, nach Trastuzumab-basierter Therapie) – Therapiekosten

Open official decision page ↗

G-BA source · retrieved 2026-08-05

Decision orientation

What the G-BA did

3 cited claims

Each claim links to the official G-BA page or an exact PDF page range.

Official metadata

Decision date
2026-05-12
Effective
15.05.2026
Action type
final resolution
Committee
Arzneimittel

Case context

Listed normative targets

directiveArzneimittel-Richtlinie
directive annexAnlage XII: Nutzenbewertung nach § 35a SGB V

A listed target is not treated as a new directive version unless an official version source exists.

Official document package